Chronic delivery of antibody fragments using immunoisolated cell implants as a passive vaccination tool.

Fiche du document

Date

2011

Type de document
Périmètre
Langue
Identifiants
Relations

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1371/journal.pone.0018268

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/21533130

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1932-6203

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_2D8D929616D21

Licences

info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer




Citer ce document

O. Marroquin Belaunzaran et al., « Chronic delivery of antibody fragments using immunoisolated cell implants as a passive vaccination tool. », Serveur académique Lausannois, ID : 10.1371/journal.pone.0018268


Métriques


Partage / Export

Résumé 0

BACKGROUND: Monoclonal antibodies and antibody fragments are powerful biotherapeutics for various debilitating diseases. However, high production costs, functional limitations such as inadequate pharmacokinetics and tissue accessibility are the current principal disadvantages for broadening their use in clinic. METHODOLOGY AND PRINCIPAL FINDINGS: We report a novel method for the long-term delivery of antibody fragments. We designed an allogenous immunoisolated implant consisting of polymer encapsulated myoblasts engineered to chronically release scFv antibodies targeted against the N-terminus of the Aβ peptide. Following a 6-month intracerebral therapy we observed a significant reduction of the production and aggregation of the Aβ peptide in the APP23 transgenic mouse model of Alzheimer's disease. In addition, functional assessment showed prevention of behavioral deficits related to anxiety and memory traits. CONCLUSIONS AND SIGNIFICANCE: The chronic local release of antibodies using immunoisolated polymer cell implants represents an alternative passive vaccination strategy in Alzheimer's disease. This novel technique could potentially benefit other diseases presently treated by local and systemic antibody administration.

document thumbnail

Par les mêmes auteurs

Sur les mêmes sujets

Exporter en